These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 29717662)
1. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662 [TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Ringheim GE; Wampole M; Oberoi K Front Immunol; 2021; 12():662223. PubMed ID: 34803999 [TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases. De Bondt M; Renders J; Struyf S; Hellings N Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213 [TBL] [Abstract][Full Text] [Related]
5. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
6. The role of Bruton's tyrosine kinase in the immune system and disease. McDonald C; Xanthopoulos C; Kostareli E Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359 [TBL] [Abstract][Full Text] [Related]
7. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus. Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834 [TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645 [TBL] [Abstract][Full Text] [Related]
9. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273 [TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). Feng Y; Duan W; Cu X; Liang C; Xin M Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232 [TBL] [Abstract][Full Text] [Related]
11. BTK Signaling in B Cell Differentiation and Autoimmunity. Corneth OBJ; Klein Wolterink RGJ; Hendriks RW Curr Top Microbiol Immunol; 2016; 393():67-105. PubMed ID: 26341110 [TBL] [Abstract][Full Text] [Related]
12. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648 [TBL] [Abstract][Full Text] [Related]